OncoSec Medical Inc.
200 South Virginia Street
8th Floor
Reno
Nevada
89501
United States
Tel: 775-562-0504
Website: http://www.oncosec.com/
Email: investors@oncosec.com
410 articles about OncoSec Medical Inc.
-
OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program
12/16/2019
OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company has received preliminary approval for a tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program for the year 2019.
-
OncoSec Presents Interim Data of 28.5% Objective Response Rate from Ongoing KEYNOTE-890 Study Evaluating TAVO™ in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer at the 2019 San Antonio
12/13/2019
4 confirmed partial responses, 3 stable disease as assessed by the investigator in 14 patients who were refractory to chemotherapy and had progressed after an average of three prior lines of therapy
-
OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value
12/9/2019
OncoSec President and CEO Daniel J. O’Connor Explains How Transaction Benefits Shareholders
-
Alpha Holdings Comments on OncoSec’s Inability to Defend China Grand Takeover
12/5/2019
Alpha Holdings, Inc., the largest stockholder of OncoSec Medical Incorporated, with an approximate 15.1% ownership stake, issued the following response to OncoSec’s most recent announcements.
-
OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
12/5/2019
San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held December 10-14, 2019.
-
OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements
12/2/2019
Strategic Investment and Partnership with CGP and Sirtex Provides an Immediate and Crucial $30 Million Cash Infusion at a Premium and Eliminates the Need to Raise Capital for the Foreseeable Future
-
In its announcement today, OncoSec said the deal is pivotal to the company’s future. It claimed that South Korea-based Alpha Holdings, which has about 15% of the company’s stock, has been making “false and misleading statements” as it urges shareholders to oppose the deal.
-
Alpha Holdings Files Class Action and Books and Records Lawsuits Against OncoSec
10/30/2019
Alleges OncoSec Board Breached Fiduciary Duty by Agreeing to China Grand Takeover Proposal at Depressed Price with No Effort to Explore Alternative Transactions or Financing Sources
-
OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market
10/21/2019
Letter to Shareholders from CEO Daniel J. O'Connor regarding the recently-announced strategic transaction with Grand Decade Developments Limited, a direct wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) (HKG:512) and its affiliate, Sirtex Medical US Holdings, Inc.
-
OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries
10/10/2019
CGP Obtains a 12-Month Option to Offer to Acquire the Remaining Shares of OncoSec at the Greater of $4.50 Per Share or 110% of the Market Price
-
OncoSec to Present at the Cantor 2019 Global Healthcare Conference
9/26/2019
OncoSec Medical Incorporated announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the Cantor 2019 Global Healthcare Conference on Thursday, October 3, 2019, at 7:45 a.m. Eastern Time in New York, NY.
-
OncoSec to Present at the Ladenburg Thalmann 2019 Healthcare Conference
9/20/2019
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019, at 3:30 p.m. Eastern Time in New York, NY.
-
OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference
9/6/2019
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9, 2019
-
OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies
7/29/2019
OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 15/561,915.
-
OncoSec Issues Letter to Shareholders
7/16/2019
OncoSec Medical Incorporated, a company developing late-stage intratumoral cancer immunotherapies, published a Letter to Shareholders from President and Chief Executive Officer, Daniel J. O'Connor.
-
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
6/27/2019
OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute,
-
OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator
6/17/2019
IVM is a powerful tool enabling real-time in vivo visualization of important immune activation and movements in tumor microenvironment driven by TAVO-PLUS
-
OncoSec to Present Immunological Data at World Pharma Week 2019
6/13/2019
Compelling Data from Multiple Clinical Trials Using Company's Biomarker Technology Support Novel Approach to Immune Resistance Mechanisms in Cancer
-
OncoSec Announces Collaboration For TAVO™ In Australia With Emerge Health
5/29/2019
OncoSec Medical Incorporated and Emerge Health Pty have entered into a collaboration agreement commercializing OncoSec's proprietary TAVO and making it available under Australia's Special Access Scheme in 2019.
-
OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility
5/28/2019
Company Now Has Cash In Excess of $30 Million, Extending Cash Runway For At Least 12 Months